Moreover, the Myeloproliferative Neoplasms Research Consortium (MPN-RC) 112 randomized trial that compared P-IFNα-2a vs. HU for the treatment of high-risk PV and ET, revealed that complete response rates were similar at 12 and 24 months, however, P-IFNα-2a was associated with a higher rate of grade 3/4 toxicity [58]. This evidence concerns the gene IFNA2 and myeloproliferative disorder.